VTCN1 and neoplasm: Moreover, tumor-expressed B7x may also alter the expression of other receptors that are highly expressed on Tregs such as OX-40, GITR, and CCR4, which have also shown to have Treg-depleting effects when targeted by therapeutic antibodies46.